A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT07478302
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Unresectable Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.

Key Dates

First listed
Mar 17, 2026
Start date
Apr 14, 2026
Status verified
Apr 2026
Primary completion
Oct 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-2524 plus bevacizumab group
    SHR-2524 plus bevacizumab combined with other drugs.

Primary Outcome Measure

Trough serum concentrations (C21d) [ Time Frame: 0 - 21 days. ]

Central Contacts

Related Studies